HPGC Renmintongtai Pharmaceutical Management
Management criteria checks 4/4
We currently do not have sufficient information about the CEO.
Key information
Cong Feng Gu
Chief executive officer
CN¥985.0k
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | less than a year |
| CEO ownership | n/a |
| Management average tenure | 3.1yrs |
| Board average tenure | 3.1yrs |
Recent management updates
Recent updates
Investors Could Be Concerned With HPGC Renmintongtai Pharmaceutical's (SHSE:600829) Returns On Capital
Jan 14
HPGC Renmintongtai Pharmaceutical Corporation's (SHSE:600829) Share Price Boosted 26% But Its Business Prospects Need A Lift Too
Dec 15Is HPGC Renmintongtai Pharmaceutical (SHSE:600829) A Risky Investment?
Oct 01HPGC Renmintongtai Pharmaceutical (SHSE:600829) Might Be Having Difficulty Using Its Capital Effectively
Sep 05CEO
Cong Feng Gu (55 yo)
Mr. Cong Feng Gu serves as Deputy General Manager and Medicine Branch Manager of Harbin Pharmaceutical Group Co., Ltd. Mr. Gu is a senior engineer. He served as an Assistant manager of Harbin Pharmaceutica...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| General Manager & Director | less than a year | CN¥985.00k | no data | |
| Deputy GM & CFO | 3.1yrs | CN¥645.00k | no data | |
| Board Secretary | 3.2yrs | CN¥217.20k | no data | |
| Chief Accountant | 10.2yrs | CN¥176.80k | no data |
Experienced Management: 600829's management team is considered experienced (3.1 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| General Manager & Director | no data | CN¥985.00k | no data | |
| Chairman of the Supervisory Board | 2.8yrs | no data | no data | |
| Chairman of the Board | 10.2yrs | CN¥1.23m | no data | |
| Independent Director | 5.8yrs | CN¥80.00k | no data | |
| Director | 1.4yrs | no data | no data | |
| Independent director | 5.8yrs | no data | no data | |
| Independent Director | 1.4yrs | no data | no data | |
| Employee Supervisor | 5.8yrs | no data | no data | |
| Supervisor | 3.1yrs | no data | no data | |
| Director | 1.4yrs | no data | no data |
Experienced Board: 600829's board of directors are considered experienced (3.1 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/23 11:44 |
| End of Day Share Price | 2025/05/23 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
HPGC Renmintongtai Pharmaceutical Corporation is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Xian Chao Zhang | China Stock Investment Research Co. Ltd. (GZ500..com) |
| Hai Zhu Peng | Huatai Research |
| Yin Ye | Ping An Securities Co. Ltd. |